Inovio Pharmaceuticals (INO) Expected to Post Earnings on Tuesday

Key Points

• Inovio is expected to report Q3 2026 results after the market closes on November 10. Analysts forecast a loss of $0.20 per share and revenue of $2.27 million; the company previously beat consensus with a quarterly loss of $0.07 per share.
• FDA approval of VOCERYQ marks a major commercial milestone for Inovio, as the treatment became the first DNA medicine approved by the agency and could create a new revenue opportunity.
• Analyst sentiment is generally positive, with HC Wainwright upgrading the stock to “Buy” and the consensus rating at “Moderate Buy” with a $4.00 average price target. Shares recently traded near $1.85 but may face volatility after a sharp rally and technically overbought conditions.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Inovio Pharmaceuticals to post earnings of ($0.20) per share and revenue of $2.27 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. On average, analysts expect Inovio Pharmaceuticals to post ($0.72) EPS for the current fiscal year and ($0.44) EPS for the next fiscal year.

Inovio Pharmaceuticals Price Performance

NASDAQ INO traded down $0.04 during trading hours on Tuesday, hitting $1.85. The company's stock had a trading volume of 27,839,886 shares, compared to its average volume of 4,296,031. Inovio Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $2.72. The company's 50 day simple moving average is $1.15 and its two-hundred day simple moving average is $1.27. The company has a market cap of $191.81 million, a P/E ratio of -2.07 and a beta of 1.61.

Key Headlines Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: FDA approves first commercial product: VOCERYQ is a DNA-based immunotherapy approved to reduce the frequency of surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-6- and HPV-11-associated disease. Inovio says it is the first DNA medicine approved by the FDA, creating a potential commercial revenue opportunity. FDA approval announcement
• Positive Sentiment: Analyst upgrade reinforces bullish sentiment: HC Wainwright raised Inovio from “Neutral” to “Buy” after the FDA decision. The upgrade adds third-party support to the investment case as the company transitions from development-stage biotechnology to commercialization. HC Wainwright upgrade
• Positive Sentiment: Price-target expectations increased: The reported average analyst price target rose 27.58% to MX$81.61, reflecting improved expectations after the regulatory approval, although the quoted target is in Mexican pesos and may not be directly comparable with U.S. dollar-based targets. Analyst price target report
• Neutral Sentiment: Momentum is technically stretched: One market report cited an hourly RSI of 82.54 after the stock’s surge, indicating overbought conditions. This supports strong near-term momentum but also raises the risk of profit-taking and volatility. Inovio technical momentum report
• Neutral Sentiment: Upcoming investor events: Inovio will present data at scientific conferences on its DNA-medicine programs, including candidates for hypophosphatasia and hemophilia A. It will also report third-quarter 2026 results on November 10, which could provide details on cash, launch plans, and VOCERYQ’s commercial outlook. Upcoming earnings announcement

Analysts Set New Price Targets

A number of brokerages have recently issued reports on INO. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, August 13th. Piper Sandler reissued an "overweight" rating and set a $4.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Zacks Research downgraded shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 12th. HC Wainwright set a $5.00 target price on shares of Inovio Pharmaceuticals and gave the stock a "buy" rating in a report on Monday. Finally, Jefferies Financial Group raised Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and increased their price target for the company from $1.80 to $3.00 in a report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inovio Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $4.00.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company's platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio's product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.